GlassScriptPhysician profile
Michael V Sharpe
NPI 1750382669
$18,246.14
in general payments reported to CMS, 2019-2025
59 companies · $2,464 in 2025
The $2,464 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,395 · 2020: $2,487 · 2021: $2,782 · 2022: $2,493 · 2023: $2,792 · 2024: $2,833 · 2025: $2,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,009 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,009.12 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,684.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,925.70 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Glaxosmithkline, LLC. | $1,583.25 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $941.38 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $836.01 | 2019-2025 | |
| Abbvie INC. | $812.73 | 2020-2025 | Qulipta, Dalvance |
| Lundbeck LLC | $684.94 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $621.29 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $610.57 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $585.72 | 2021-2025 | |
| Abbott Laboratories | $552.32 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $536.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $524.94 | 2019-2025 | Trintellix, Gattex |
| Amgen INC. | $492.30 | 2019-2025 | Repatha, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $461.63 | 2019-2024 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sharpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.